Lipopolysaccharide-induced podocyte injury is regulated by calcineurin/NFAT and TLR4/MyD88/NF-κB signaling pathways through angiopoietin-like protein 4

Xiujin Shen, Chunhua Weng, Yucheng Wang, Cuili Wang, Shi Feng, Xiayu Li, Heng Li, Hong Jiang, Haibing Wang, Jianghua Chen

KEYWORDS
Angiopoietin-like protein 4; Calcineurin/NFAT; LPS;

Abstract Podocyte injury is an important cause of proteinuria. Angiopoietin-like protein 4 (Angptl4) is a secreted glycoprotein and has a role in proteinuria. However, the exact role of Angptl4 in podocyte injury and its upstream regulators has not been clarified. In this study, we used lipopolysaccharide (LPS)-induced mice and cultured podocytes as podocyte injury models. Our results indicated that LPS increased the expression of podocyte Angptl4 in vivo and in vitro. Furthermore, we showed that Angptl4 overexpression deteriorated LPS-induced podocyte injury.
Introduction

Podocyte related nephropathy, including minimal change nephropathy (MCD), focal segmental glomerulosclerosis (FSGS), diabetic kidney disease (DKD) and membranous nephropathy (MN), are glomerular diseases characterized by structural and functional change of podocytes.1,2 Podocyte injury reduces the expression of podocyte-specific proteins synaptopodin and podocin, leading to the disorder of podocyte cytoskeleton and fusion of foot processes, resulting in proteinuria and ultimately renal dysfunction.3 The molecular mechanism of podocyte injury has been extensively studied. Recent studies indicated that molecules such as Angptl4, suPAR, B7-1 and ATF3 were implicated in podocyte injury.4–7 Ducasa GM et al demonstrated that reduced ATP-binding cassette A1 was involved in mitochondria dysfunction of podocytes, which was susceptible to the development of DKD.8 Wu J et al showed that decreased miR-30 in damaged podocytes, and therapies targeting miR-30 could alleviate podocyte injury in different levels.9 However, the molecular mechanisms are still complex, and need further exploration.

Angiopoietin-like protein 4 (Angptl4) is a member of the angiopoietin-like protein family, which mainly participates in lipid metabolism by suppressing the activity of lipoprotein lipase (LPL). Angptl4 plays a vital role in angiogenesis, cancer, and coronary heart disease.10–12 In addition, Angptl4 also participate in inflammatory diseases such as diabetes mellitus, rheumatoid arthritis, pneumonia, and atherosclerosis.13–16 It has been found that influenza viruses promoted the expression of Angptl4 in lung through the IL-6-STAT3 signaling pathway, thereby improved the leakage of lung tissue and accelerated lung injury.14 Nevertheless, Angptl4 played an anti-inflammatory role through macrophages in atherosclerosis, and they found that Angptl4 inhibited systemic inflammatory response induced by saturated fatty acids through inhibiting the absorption of fatty acids by macrophages of mesenteric lymph nodes.17 These results suggest that Angptl4 is closely related to inflammation and is an essential inflammatory regulator, but its role varied in different organs.

In the kidney, Clement LC et al firstly demonstrated that the upregulation of Angptl4 in podocytes was involved in the occurrence of proteinuria and hyperlipidemia,4 and therapies targeting podocyte Angptl4 reduced hyperlipidemia and proteinuria. In addition, podocyte Angptl4 also participated in membranous nephropathy and diabetic nephropathy.18,19 Furthermore, there was also a significant correlation between Angptl4 gene polymorphism and proteinuria after renal transplantation.20 However, the exact role of Angptl4 in podocyte injury and its upstream regulators has not been clarified.

To demonstrate the mechanism of Angptl4 in podocyte injury and its upstream regulators, we used LPS-induced model of podocyte injury in vivo and in vitro, which is expected to provide new ideas for understanding the mechanism of LPS-induced podocyte injury and treatment strategies.

Materials and methods

Animal experiments

Adult male BALB/c mice (20–25 g) were provided by the Shanghai Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China). The procedures were accord with the Guidelines for the Care and Use of Laboratory Animals. Mice were randomly divided into four groups. For the podocyte injury model, mice were administrated with a single intraperitoneal injection of LPS (10 mg/kg body weight, L2880, Sigma). For the LPS plus FK506 treatment group, FK506 (Fujisawa Pharmaceutical, Japan) was intragastrically administrated at the dose of 2 mg/kg at the same time with LPS injection. For the LPS plus CsA treatment group, CsA (Novartis Pharmaceutical, Switzerland) was intraperitoneally injected at the dose of 20 mg/kg at the same time with LPS injection. The control mice were administrated the same volume of 0.9% saline. After 24 h, the mice were anesthetized with pentobarbital sodium, serum and urine were subsequently collected.

Transmission electron microscopy and measurement of foot process width

Renal cortex samples (1 mm3) were fixed in 2.5% glutaraldehyde, detailed steps for transmission electron microscopy, and the measurement of foot process width was referred to as previous literature.21

Isolatation of mouse glomeruli

Adult male BALB/c mice were anesthetized and perfused with 3 mg/ml Fe3O4 diluted in PBS via the left ventricle.
The kidneys were decapsulated, cut into 1 mm³ pieces, and digested in 2 mg/ml collagenase A in water bath at 37 °C for about 40 min with gentle shake. The digested kidney tissues were re-suspended in 5 ml of cold HBSS and then pressed through a 100 μm cell strainer. The cell suspension was centrifuged at 800 rpm for 5 min. After that, the cell pellet was re-suspended in 1 ml of HBSS and gathered by a magnet. The gathered mouse glomeruli were examined with microscopy (Leica DMLB, Wetzlar, Germany) to observe the purity of the gathered glomeruli, and the pellet was used for RNA isolation.

Quantitative real-time PCR

Total RNA was extracted with an RNA extraction kit (ZYMO research, CA, USA) following the manufacturers’ instructions. cDNA was reversely transcribed with a PrimeScript RT reagent kit (Takara Biotechnology, Dalian, China). PCR reaction was performed with SYBR Green Mix (Vazyme, Nanjing, China). Quantitative RT-PCR was performed using a CFX96 system (Bio-Rad, USA). The mRNA expression level was quantified using 2⁻¹⁺ⁿزاد methods. The primers in this experiment were listed in Table S1.

Enzyme-linked immunosorbent assay (ELISA)

The concentration of mouse Angptl4 from serum and urine samples was determined via ELISA (ab216789, Abcam, USA).

Figure 1  LPS induces the expression of Angptl4 in podocytes in vivo. (A) Immunofluorescence staining of synaptopodin (red) and podocin (red) in normal and LPS-treated mouse glomerulus. Scale bar = 20 μm. (B) Transmission electron microscopy analysis of foot process fusion in control and LPS-induced mice. Scale bar = 2 μm. (C) mRNA detection of kidney Angptl4 at 24 h after LPS induction. (D, E) ELISA detection of serum and urine Angptl4 in LPS-induced mice. (F) mRNA detection of Angptl4 in separated mouse glomerulus and tubules at 24 h after LPS induction. (G) Western blot analysis and quantification of Angptl4 expression in LPS-induced glomerulus. All values were presented as mean ± SD, n ≥ 3. *P < 0.05 versus control group, **P < 0.01 versus control group, ***P < 0.001 versus control group, ****P < 0.0001 versus control group using a two-tailed Student’s t test.
ml, L4391, Sigma), CsA (5 μg/ml, C1832, Sigma), FK506 (10 μg/ml, F4679, Sigma), TAK-242 (1 μM, HY-11109, MCE), Ionomycin (0.5 μM, I0634, Sigma) or PDTC (20 μM, S1808, Beyotime) for indicated time. Mouse Glomerular Endothelial cells (mGEnC) was provided by Professor Chuanming Hao at Ruijin Hospital, and were cultured in RPMI 1640 medium with 10% FBS in a humidified atmosphere of 5% CO₂. Human Mesangial Cells (HMC) was bought from ATCC, and was cultured in DMEM medium with 10% FBS in a humidified atmosphere of 5% CO₂.

Figure 2  LPS increases podocyte Angptl4 in vitro. (A) Immunofluorescence staining of F-actin (green) and synaptopodin (red) in control and LPS-treated podocytes. Scale bar = 50 μm. (B) Western blot detection and quantification of synaptopodin in normal and LPS-treated podocytes. Comparison between control and LPS group was made using a two-tailed Student’s t test. (C) mRNA detection of Angptl4 at 24 h after 0, 5, 10 or 20 μg/ml LPS induction. (D, E) Western blot detection and quantification of supernatant (CM: conditioned medium) and cellular (cell lysis) Angptl4 at 24 h after 0, 5, 10 or 20 μg/ml LPS induction. (F) mRNA detection of Angptl4 at 0 h, 3 h, 6 h, and 24 h after 20 μg/ml LPS induction. (G, H) Western blot detection and quantification of supernatant and cellular Angptl4 at 0 h, 3 h, 6 h and 24 h after 20 μg/ml LPS induction. All values were presented as mean ± SD, n = 3. Data from multiple groups were made using one-way ANOVA followed by Turkey’s method. *P < 0.05 versus control group, **P < 0.01 versus control group, ****P < 0.0001 versus control group.
Small interfering RNA (siRNA) transfection

The siRNAs were synthesized at the GenePharma company. The sequences of siRNAs in the experiments were shown in Table S2. The siRNA transfection was performed with lipofectamine RNAiMAX (Life, USA) transfection protocols in differentiated podocytes. The specificity for siRNA mediated gene silencing was performed 48 h after siRNA transfection for RT-PCR and western blot analysis.

Lentiviral infection

PLKO.1-puro (EV) and PLKO.1-puro-Angptl4 (Angptl4-OE) lentivirus were purchased from Vigene biotechnology (Jinan, China). U6-puro (NC) and U6-puro-Angptl4 shRNA (Angptl4-KD) lentivirus were obtained from the Genechem company (Shanghai, China). Mouse podocytes at about 80% confluence were infected with Angptl4 overexpressed and Angptl4 shRNA lentivirus according to the manufacturer’s

Figure 3  Angptl4 deteriorates LPS-induced podocyte injury. (A, B) mRNA and western blot quantification of Angptl4 in EV and Angptl4-OE podocytes. (C) Western blot quantification of synaptopodin in EV and Angptl4-OE podocytes before or after LPS induction. (D) Immunofluorescence staining of F-actin (green) and synaptopodin (red) in EV and Angptl4-OE podocytes before or after LPS induction. Scale bar = 50 μm. (E, F) mRNA and western blot quantification of Angptl4 in NC and Angptl4-KD podocytes. (G) Western blot quantification of synaptopodin in NC and Angptl4-KD podocytes before or after LPS induction. (H) Immunofluorescence staining of F-actin (green) and synaptopodin (red) in NC and Angptl4-KD podocytes before or after LPS induction. Scale bar = 50 μm. All values were presented as mean ± SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using one-way ANOVA followed by Turkey’s method.
Figure 4  Effect of TLR4/MyD88/NF-κB on the expression of Angptl4 in cultured podocytes. (A, B) RT-PCR and western blot quantification of Angptl4 in LPS-induced podocytes after TAK-242 treatment. (C) Western blot analysis of TLR4, MyD88, and Angptl4 in NC and TLR4 siRNA-treated podocytes before or after LPS induction. (D) Western blot analysis of TLR4, MyD88, and Angptl4 in NC
Transfected podocytes were screened by puromycin selection. The specificity of Angptl4 was performed with RT-PCR and ELISA analysis.

**Western blot analysis**

Cultured mouse podocytes and isolated renal glomerulus were lysed with RIPA buffer to gain total proteins. For cell culture supernatants, 10 ml of culture medium was concentrated with 50 ml Amicon Ultra Centrifugal Filters (Millipore, MA, USA) to about 200 µl for further analysis. The protein samples were separated on SDS-PAGE gels and transferred to PVDF membranes (Millipore, Temecula, CA). PVDF membranes were blocked with 5% non-fat milk for 2 h and incubated with different primary antibodies. The primary antibodies were used as follows: Angptl4(1:1000, Abcam); synaptopodin (1:1000, Santa Cruz); CaN (1:500, Santa Cruz); GAPDH(1:5000, Bioke); β-actin (1:5000, Bioke); TLR4 (1:500, Santa Cruz); CD14 (1:1000, Cell Signaling); MyD88(1:1000, Cell Signaling); p-p65 (1:1000, Cell Signaling); p-p65 (1:1000, Cell Signaling); p65 (1:1000, Cell Signaling); NFATc1 (1:500, Santa Cruz); HIF-1α (1:1000, Cell Signaling). After incubation with HRP-conjugated secondary antibodies for 2 h, membranes were visualized with an enhanced chemiluminescence detection system ChemiDoc MP (Bio-RAD, California, USA).

**Statistical analysis**

Data are presented as mean ± SD. The quantitative results were analyzed with GraphPad Prism 7 software. Comparisons between two groups were made using a two-tailed Student’s t test. Data from multiple groups were made using one-way ANOVA followed by Turkey’s method. *P < 0.05 was considered to indicate statistical significance.

**Results**

**LPS induces the expression of Angptl4 in podocytes**

First, we successfully established the LPS-induced podocyte injury model in vivo. As shown in Fig. 1A, LPS decreased the expression of synaptopodin and podocin compared to normal controls. The electron microscopy also indicated no apparent difference between normal (NC) and Angptl4 knockdown Angptl4-KD) podocytes (Fig. 1C, D). The ELISA detection showed that serum Angptl4 was increased while serum Angptl4 was decreased in LPS-induced mice, which was further disorganized after LPS induction (Fig. 1D, E).

Angptl4 deteriorates LPS-induced podocyte injury

We next determined the effect of Angptl4 on podocyte injury. First, we successfully established Angptl4 overexpressed (Angptl4-OE) podocytes (Fig. 3A, B). Moreover, synaptopodin was decreased in Angptl4-OE podocytes, especially after LPS induction (Fig. 3C, D; Fig. S2a). The immunofluorescence staining of F-actin showed decreased, disorganized and shortened actin stress fibers in Angptl4-OE podocytes compared to the control (EV) podocytes, which was further disorganized after LPS induction (Fig. 3D; Fig. S2a).

To further verify the role of Angptl4 in podocytes, we knocked down Angptl4 in podocytes (Fig. 3E, F). Immunofluorescence staining of F-actin and synaptopodin indicated no apparent difference between normal (NC) and Angptl4 knockdown (Angptl4-KD) podocytes (Fig. S2b). Furthermore, the Angptl4 knockdown partially recovered the expression of synaptopodin after LPS induction compared to the control group (Fig. 3G, H). Moreover, we showed that Angptl4-KD podocytes restored LPS-induced F-actin rearrangement compared to the control podocytes (Fig. 3H). These results demonstrated that Angptl4 overexpression aggravated LPS-induced podocyte cytoskeleton and decreased the expression of synaptopodin, implying the role of Angptl4 in LPS-induced podocyte injury.

and MyD88 siRNA-treated podocytes before or after LPS induction. (E) Western blot analysis of p65 phosphorylation at 0 h, 3 h and 6 h after LPS induction. (F) Western blot analysis of p65 phosphorylation in NC and TLR4 siRNA-treated podocytes before or after LPS induction. (G) Western blot analysis of p65 phosphorylation in NC and MyD88 siRNA-treated podocytes before or after LPS induction. (H) Western blot quantification of Angptl4 and synaptopodin in LPS-induced mouse podocytes after PDTC treatment. (I) Immunofluorescence staining of F-actin (green) and synaptopodin (red) in PDTC pretreated cultured podocytes at 24 h after LPS induction. Scale bar = 50 µm. All values were presented as mean ± SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using one-way ANOVA followed by Turkey’s method.
TLR4/MyD88/NF-κB signaling is involved in the upregulation of Angptl4 in LPS-induced podocytes

LPS stimulation generally triggers the TLR4/MyD88/NF-κB signaling pathway. We then detected the effect of TLR4 and the co-receptor CD14 on Angptl4 expression. As shown in Figure S3a, b, the expression of CD14 was promoted as LPS concentration increased. We then knocked down CD14 in podocytes (Fig. S3c), the results showed that CD14 knockdown inhibited CD14 and Angptl4 expression in LPS-induced podocytes (Fig. S3d, e). We next treated podocytes with TLR4 specific inhibitor TAK-242, the results showed that TAK-242 inhibited Angptl4 mRNA and protein in podocytes (Fig. 4A, B). Subsequently, we showed that both TLR4 and MyD88 siRNA decreased the expression of Angptl4 in LPS-induced podocytes. Moreover, TLR4 siRNA inhibited the downstream molecule MyD88 while MyD88 siRNA had no effect on TLR4 (Fig. 4C, D). We also found the phosphorylation of p65 in LPS-induced podocytes (Fig. 4E). TLR4 and MyD88 siRNA also decreased p65 phosphorylation after LPS induction in podocytes (Fig. 4F, G). In addition, we indicated that PDTC, a NF-κB inhibitor, promoted the recovery of synaptopodin and F-actin expression (Fig. 4H, I) and had a significant inhibitory effect on Angptl4 expression (Fig. 4I), indicating that TLR4/MyD88/NF-κB signal pathway mediated LPS-induced Angptl4 in podocyte injury.

Calcineurin/NFAT signaling mediates LPS-induced Angptl4 expression

Previous studies have implied the role of the calcineurin/NFAT signaling pathway on Angptl4 regulation. Our results showed that LPS prompted the CaN expression and increased the percentage of nuclear NFATC1+ podocytes (Fig. 5A, B), which was inhibited by calcineurin inhibitors CsA or FK506 intervention (Fig. 5C, D), implicating a promoting effect of LPS on calcineurin/NFAT signaling pathway. Moreover, we indicated that CaN siRNA inhibited LPS-induced Angptl4 expression in podocytes (Fig. 5E). Our in vivo and in vitro results also indicated that CsA or FK506 treatment inhibited LPS-induced Angptl4 expression at mRNA and protein level (Fig. 5F, G, J, K), the ELISA results showed that urine Angptl4 was decreased in CsA or FK506 treatment group compared to the LPS-induced group (Fig. 5H, I). Subsequently, we stimulated podocytes with ionomycin, the results showed that ionomycin increased cellular and secreted Angptl4 in a dose-dependent manner, and the effect was inhibited by CsA or FK506 intervention (Fig. 5L, M).

Besides inhibiting the expression of Angptl4, our in vivo results indicated that CaN inhibitors CsA or FK506 treatment inhibited LPS-induced proteinuria (Fig. 6A, B). PAS staining showed no significant changes between groups (Fig. 6C). Electron microscopy indicated that CsA or FK506 treatment partially reversed foot process effacement (Fig. 6D). CsA or FK506 treatment also decreased synaptopodin and podocin in LPS-induced glomerulus and podocytes (Fig. 6E-G). These results imply that CaN inhibitors can be used to treat podocyte related kidney diseases partially through regulating Angptl4 expression.

Discussion

Here, this study shows for the first time that LPS increased podocyte Angptl4 expression in the in vitro and in vivo model. Furthermore, the Angptl4 overexpression and knockdown experiment indicated that Angptl4 promoted the disorder of podocyte cytoskeleton and decreased synaptopodin expression. In addition, our results implied that both of the TLR4/MyD88/NF-κB and calcineurin/NFAT signaling mediated the upregulation of Angptl4 in LPS-induced podocytes.

Previous results have indicated that many molecules and pathways participated in LPS-induced podocyte injury. Zhang H et al showed ATF3 induction was involved in LPS-induced podocyte injury through NFAT signaling pathway. Another study of Senotheai S et al indicated that Fractalkine participated in LPS-induced podocyte injury through the Wnt/β-catenin pathway. CD80 also participated in LPS-induced podocyte injury induced by LPS. It was reported that the down-regulation of miRNA-30 also facilitated LPS-induced podocyte injury. We are the first to indicated that Angptl4 also contributed to LPS-induced podocyte injury.

It was demonstrated that LPS differentially regulated Angptl4. A study by Brown R et al firstly found that LPS increased Angptl4 expression in brain tissue. Another study found that LPS increased Angptl4 in lung, heart, muscle, bone marrow, and adipose tissue. Nevertheless, in a study of Feingold KR et al, they found LPS markedly decreased Angptl4 in mouse peritoneal macrophage. Our results indicated that Angptl4 was increased in LPS-induced podocytes in vivo and in vitro. In addition, we also noticed that only podocytes showed an increase in Angptl4 expression in LPS-stimulated kidneys, other glomerular cells such as mesangial cells, glomerular endothelial cells, and tubular cells showed no significant changes, suggesting that there might be some particular pathway or protein regulating Angptl4 expression in podocytes, which needs further experiments to verify. Moreover, in the in vivo mouse model, we found LPS decreased serum Angptl4 while increased urine Angptl4, part of the explanation might be that most of Angptl4 secreted by podocytes leaked into renal tubules, and excreted from urine, resulting in an increase in urine Angptl4.

Previous reports showed that Angptl4 had a dual role in different diseases. In cancers, Zhu P et al found that Angptl4 stimulated tumor cells to escape anoikis. However, in hepatocellular carcinoma, bladder cancer and cholangiocarcinoma, Angptl4 promoted cell apoptosis and played as a tumor suppressor gene. Concerning to Angptl4 in podocytes, Clement LC et al firstly found that PAN-induced rats showed low sialic acid Angptl4 secretion from podocytes into the basement membrane, which altered the charge barrier on GBM, causing foot process fusion, and eventually inducing proteinuria. In our experiment, we showed decreased, disorganized and shortened actin stress fibers in Angptl4-GE podocytes compared to the EV podocytes, especially after LPS induction, implying a direct effect of Angptl4 in inducing podocyte injury.

The mechanism of Angptl4 upstream regulation during podocyte injury is not clear. Previous reports have shown
Figure 5  Effect of Calcineurin/NFAT on the expression of Angptl4 in cultured podocytes. (A) RT-PCR detection of CaN in control and LPS-induced podocytes. Scale bar = 20 μm. (B) Immunofluorescence staining and quantification of nuclear NFATc1 (red) in LPS-induced podocytes. Scale bar = 20 μm. (C) RT-PCR quantification of CaN in LPS-induced podocytes after CsA or FK506 pre-treatment. (D) Immunofluorescence staining and quantification of nuclear NFATc1 (red) in LPS-induced podocytes after CsA or FK506 pre-treatment. Scale bar = 20 μm. (E) Western blot analysis of CaN and Angptl4 in normal control and CaN siRNA podocytes before or after LPS induction. (F, G) RT-PCR and western blot quantification of Angptl4 in LPS-induced glomerulus after CsA or FK506 treatment. (H, I) ELISA detection of serum and urine Angptl4 in LPS-induced mice after CsA or FK506 treatment. (J) RT-PCR quantification of Angptl4 in LPS-induced cultured mouse podocytes after CsA or FK506 treatment. (K) Western blot analysis and quantification of cellular and cultural supernatant Angptl4 in LPS-induced mouse podocytes after CsA or FK506 treatment. (L) Western blot analysis of cellular and cultural supernatant Angptl4 expression at different concentrations of ionomycin induction in podocytes. (M) Western blot analysis of podocyte cellular and cultural supernatant Angptl4 before or after CsA or FK506 treatment in ionomycin-induced cultured podocytes. All values were presented as mean ± SD, n ≥ 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using one-way ANOVA followed by Turkey’s method.
Figure 6  CaN inhibitors protect from LPS-induced podocyte injury. (A, B) CsA and FK506 decreased LPS-induced urinary protein in mice. (C) PAS staining of CsA or FK506 pretreatment in LPS-induced mice. Scale bar = 20 μm. (D) Transmission electron microscopy analysis of CsA or FK506 pretreatment in LPS-induced mice. Scale bar = 2 μm. (E) Immunofluorescence staining of synaptopodin (red) and podocin (red) in CsA or FK506 pretreated mice at 24 h after LPS induction. Scale bar = 10 μm. (F) Immunofluorescence staining of F-actin (green) and synaptopodin (red) in CsA or FK506 pretreated cultured podocytes at 24 h after LPS induction. Scale bar = 50 μm. (G) Western blot analysis of synaptopodin in CsA or FK506 pretreated cultured podocytes at 24 h after LPS induction. (H) Schematic diagram indicates LPS-induced podocyte Angptl4 is mediated by TLR4/MyD88/NF-κB and calcineurin/NFAT signal pathways. All values were presented as mean ± SD, n ≥ 3. *P < 0.05 versus LPS group, **P < 0.01 versus LPS group, ***P < 0.001 versus LPS group, ****P < 0.0001 versus LPS group using one-way ANOVA followed by Turkey’s method.
that Angptl4 was mainly affected by HIF and PPAR signaling pathways. 

Our results showed that LPS had no effect on HIF-1α, PPAR-γ, or PPAR-α in podocytes (Fig. 5A–C), implying that the HIF and PPAR signaling pathways might not participate in LPS-induced Angptl4 in podocytes. LPS played roles through the TLR4/MyD88/ NF-κB signaling pathway. As one of the co-receptors of LPS, CD14 was involved in podocyte related nephropathy. Poensen et al showed that the urine sCD14 of nephrotic syndrome patients was significantly higher than healthy control and IgA nephropathy patients without nephrotic syndrome. A study of Kang MJ et al found that soluble CD14 (sCD14) was positively correlated with the severity of proteinuria. Our results indicated that LPS increased the expression of CD14 in podocytes. Meanwhile, CD14 knockdown experiment showed decreased expression of Angptl4, indicating that Angptl4 was partially regulated by CD14. TLR4 has been implied that the TLR4/MyD88/NF-κB signaling pathwayregulated Angptl4 expression in podocytes. 

Calcineurin/NFAT signaling is a crucial signaling pathway for proteinuria production and podocyte injury. 

Calcineurin inhibitors have been reported to inhibit Angptl4 expression in diabetic nephropathy and membrane nephropathy, implying that Angptl4 might be regulated by calcineurin/NFAT signaling pathway in podocytes. Our results found that Calcineurin inhibitors and CaN siRNA markedly inhibited LPS-induced podocyte injury as well as Angptl4 expression. In addition, we also found a similar effect in heart, lung, and adipose tissues (Fig. S5), implying that the Angptl4 was not only the target in podocytes. Furthermore, we showed that the NFATc1 activator also promoted Angptl4 expression. A study by Ivan Zanoni et al demonstrated that the calcineurin/NFAT signaling pathway could also be affected by LPS, leading to apoptosis and inflammation of dendritic cells. 

Combined with these findings, we speculated that LPS-induced podocyte Angptl4 was also regulated by the calcineurin/NFAT signaling pathway. 

In addition to the above signaling pathways, we also noticed that some other signaling pathways also regulated Angptl4 expression. A study by Ma and colleagues showed that Angptl4 promoted Viral G protein-coupled receptor-mediated angiogenesis and vascular permeability through the Rho-ROCK pathway. Angptl4 could also counteract hypoxia-induced vascular permeability by modulating the src signaling pathway. Recently, it was found that TGF-β regulated the expression of Angptl4 via a smad3-signaling pathway to promote lung metastasis of breast tumors. Li L et al also show that influenza infection increased Angptl4 through an IL-6-STAT3-mediated mechanism to enhance pulmonary tissue leakiness and exacerbate inflammation-induced lung damage. These results implied the complexity of Angptl4 upstream regulation. 

In summary, our study revealed that Angptl4, induced by LPS induction, deteriorated LPS-induced podocyte cytoskeleton rearrangement and decreased the expression of synaptopodin. Furthermore, we showed that both of the TLR4/MyD88/NF-κB and calcineurin/NFAT signaling mediated the upregulation of Angptl4 in LPS-induced podocytes, which might be a therapeutic target for podocyte nephropathy treatment. 

Author contributions

X.J.S and J.H.C conceived this study; X.J.S designed the project; X.J.S and H.B.W drafted the manuscript; X.J.S performed the experiments; H.B.W helped with the western blot experiment; Y.C.W and C.L.W performed the animal experiments; C.H.W offered valuable suggestions for the transfection experiments; H.J gave suggestions for drafting the manuscript; S.F helped to culture podocytes. X.Y.L and H.L offered valuable suggestions for the usage of calcineurin inhibitors. 

Conflict of interests

All the authors declared no competing interests. 

Funding

This study was supported by the National Natural Science Foundation of China (No. 81400716), the Zhejiang Provincial Natural Science Foundation of China (No. LY20H050007, LY19H050005) and Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (No. 2020383770). 

Acknowledgements

We thank Professor Shengqiang Yu at Shanghai Changzheng Hospital for providing conditionally immortalized mouse podocytes and Professor Chuanming Hao at Ruijin Hospital for donating mouse glomerular endothelial cells. 

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jendis.2020.07.005. 

References

1. Jourde-Chiche N, Fakhouri F, Dou L, et al. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol. 2019;15(2):87–108.
2. Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzelis JF. Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol. 2016;12(12):768–776.
3. Sever S, Schiffer M. Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases. Kidney Int. 2018;93(6):1298–1307.
4. Clement LC, Avila-Casado C, Mace C, et al. Podocyte-secreted angiopeptin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med. 2011;17(1):117–122.
5. Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Investig. 2004;113(10):1390–1397.
6. Zhang H, Liang S, Du Y, et al. Inducible ATF3-NFAT axis aggravates podocyte injury. *J Mol Med (Berl)*. 2018;96(1):53–64.

7. Wei C, El Hundi S, Li J, et al. Circulating urikase receptor as a cause of focal segmental glomerulosclerosis. *Nat Med*. 2011;17(8):952–960.

8. Ducasa GM, Mitrofanova A, Mallela SK, et al. ATP-binding cassette A1 deficiency causes cardiopulmonary-driven mitochondrial dysfunction in podocytes. *J Clin Investig*. 2019;129(8):3387–3400.

9. Wu J, Zheng C, Wang X, et al. MicroRNA-30 family members regulate calcium/calcineurin signaling in podocytes. *J Clin Investig*. 2015;125(11):4091–4106.

10. Dewey FE, Gusarova V, O’Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. *N Engl J Med*. 2016;374(12):1123–1133.

11. Huang RL, Teo Z, Chong HC, et al. ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. *Blood*. 2011;118(14):3900–4002.

12. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. *Nat Cell Biol*. 2013;15(2):201–213.

13. Georgiadi A, Wang Y, Stienstra R, et al. Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development. *Arterioscler Thromb Vasc Biol*. 2013;33(7):1529–1537.

14. Li L, Chong HC, Ng SY, et al. Angiopoietin-like 4 increases pulmonary tissue leakiness and damage during influenza pneumonia. *Cell Rep*. 2015;10(5):654–663.

15. Guo L, Li S, Zhao Y, et al. Silencing angiopoietin-like protein 4 (ANGPTL4) protects against lipopolysaccharide-induced acute lung injury via regulating SIRT1/FOXO3A pathway. *J Cell Physiol*. 2015;230(10):2390–2402.

16. Yang LY, Yu CG, Wang XH, et al. Angiopoietin-like protein 4 is a high-density lipoprotein (HDL) component for HDL metabolism and function in nondiabetic participants and type 2 diabetic patients. *J Am Heart Assoc*. 2017;6(6):e005973.

17. Lichtenstein L, Mattissen F, de Wilt NJ, et al. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. *Cell Metab*. 2010;12(6):580–592.

18. Peng L, Ma J, Cui R, et al. The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4. *PLoS One*. 2014;9(8):e106164.

19. Ma J, Chen X, Li JS, et al. Upregulation of podocyte-secreted angiopoietin-like-4 in diabetic nephropathy. *Endocrine*. 2015;49(2):373–384.

20. Chang Y, Shah T, Yang J, Min DI. Association of genetic polymorphisms of angiopoietin-like 4 with severity of posttransplant proteinuria in kidney allograft recipients. *Transpl Immunol*. 2017;40:35–41.

21. Shen X, Jiang H, Ying M, et al. Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. *Sci Rep*. 2016;6:32087.

22. Senouthis S, Wang J, Fu D, You Y. Fractalkine is involved in lipopolysaccharide-induced podocyte injury through the Wnt/beta-catenin pathway in an acute kidney injury mouse model. *Inflammation*. 2019;42(4):1287–1300.

23. Brown R, Imran SA, Wilkinson M. Lipopolysaccharide (LPS) stimulates adipokine and socs3 gene expression in mouse brain and pilatory gland in vivo, and in N1 hypothalamic neurons in vitro. *J Neuroimmunol*. 2009;209(1–2):96–103.

24. Lu B, Moser A, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response stimulates the expression of angiopoietin-like protein 4. *Biochem Biophys Res Commun*. 2010;391(4):1737–1741.

25. Feingold KR, Shigenaga JK, Cross AS, Moser A, Grunfeld C. Angiopoietin-like protein 4 expression is decreased in activated macrophages. *Biochem Biophys Res Commun*. 2012;421(3):612–615.

26. Zhi P, Tan MJ, Huang RL, et al. Angiopietin-like-4 protein elevates the prosurvival intracellular O2(·)-H2O2 ratio and confers anoikis resistance to tumors. *Cancer Cell*. 2011;19(3):401–415.

27. Ng KT, Xu A, Cheng Q, et al. Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hematopoietic cancer. *Mol Cancer*. 2014;13:196.

28. Hsieh HY, Jou YC, Tung CL, et al. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the uterine leiomyoma microenvironment. *Oncogene*. 2018;37(5):673–686.

29. Yu Y, Zhang M, Liu J, et al. Long non-coding RNA VPT1 promotes cell proliferation and migration by silencing ANGPTL4 expression in cholangiocarcinoma. *Mol Ther Nucleic Acids*. 2018;13:503–513.

30. Inoue T, Kohro T, Tanaka T, et al. Cross-enhancement of ANGPTL4 transcription by HIF1 alpha and PPAR beta/delta is the result of the conformational proximity of two response elements. *Genome Biol*. 2014;15(4):R63.

31. Li H, Ge C, Zhao F, et al. Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin beta1 signaling in human hepatocellular carcinoma. *Hepatology*. 2011;54(3):910–919.

32. Liu L, Zhuan X, Jiang M, Guan F, Fu Q, Lin J. ANGPTL4 mediates the protective role of PPARgamma activators in the pathogenesis of preeclampsia. *Cell Death Dis*. 2017;8(9):e3054.

33. Poesen R, Ramezani A, Claes K, et al. Associations of soluble CD14 and endotoxin with mortality, cardiovascular disease, and progression of kidney disease among patients with CKD. *Clin J Am Soc Nephrol*. 2015;10(9):1525–1533.

34. Kang MJ, Park YJ, You S, et al. Urinary proteome profile predictive of disease activity in rheumatoid arthritis. *J Proteome Res*. 2014;13(11):5206–5217.

35. Liu Y, Xu Z, Ma F, Jia Y, Wang G. Knockdown of TLR4 attenuates high glucose-induced podocyte injury via the NALP3/ASC/Caspase-1 signaling pathway. *Biomed Pharmacother*. 2018;107:1393–1401.

36. Verzola D, Cappuccino L, D’Amato E, et al. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. *Kidney Int*. 2014;86(6):1229–1243.

37. Saurus P, Kussela S, Lehtonen E, et al. Podocyte apoptosis is prevented by blocking the Toll like receptor pathway. *Cell Death Dis*. 2015;6(5):e1752.

38. Schumacher A, Denecke B, Braunschweig T, et al. Angiotensin II is upregulated under inflammatory conditions in the bone marrow of mice, expands myeloid progenitors, and accelerates reconstitution of platelets after myelosuppressive therapy. *J Hematol Oncol*. 2015;8:64.

39. Wang Y, Jarad G, Tripathi P, et al. Activation of NFAT signaling in podocytes causes glomerulosclerosis. *J Am Soc Nephrol*. 2010;21(10):1657–1666.

40. Wang L, Chang JH, Paik SY, Tang Y, Eisner W, Spurney RF. Calcineurin (CN) activation promotes apoptosis of glomerular
podocytes both in vitro and in vivo. Mol Endocrinol. 2011;25(8):1376–1386.

41. Zhang B, Shi W, Ma J, et al. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med (Berl). 2012;90(12):1407–1420.

42. Zhang L, Li R, Shi W, et al. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice. Br J Pharmacol. 2013;170(2):426–439.

43. Zanoni I, Ostuni R, Capuano G, et al. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature. 2009;460(7252):264–268.

44. Ma T, Jham BC, Hu J, et al. Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi’s sarcoma. Proc Natl Acad Sci US A. 2010;107(32):14363–14368.

45. Gomez Perdiguero E, Liabotis-Fontugne A, Durand M, et al. ANGPTL4-alphavbeta3 integrin interaction counteracts hypoxia-induced vascular permeability by modulating Src signalling downstream of VEGFR2. J Pathol. 2016;240(4):461–471.

46. Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77.